Cargando…

Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia

This study reports the integrated analysis of two phase III studies of novel β-lactam/β-lactamase combination versus meropenem for treating nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP). The ASPECT-NP trial compared the efficacy and safety of ceftolozane–tazobactam versus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Wei-Ting, Lai, Chih-Cheng, Cheong, Chong-Un
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963743/ https://www.ncbi.nlm.nih.gov/pubmed/31766123 http://dx.doi.org/10.3390/antibiotics8040219

Ejemplares similares

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
por: Duda-Madej, Anna, et al.
Publicado: (2023)

Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis
por: Cang, Huai Qin, et al.
Publicado: (2023)

Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors
por: Reddy, Nakita, et al.
Publicado: (2023)

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020
por: Sader, Helio S., et al.
Publicado: (2021)

Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis
por: Lal, Ashima, et al.
Publicado: (2016)

Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens
por: Seok, Hyeri, et al.
Publicado: (2019)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
por: Luci, Giacomo, et al.
Publicado: (2021)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
por: Aslan, Abdullah Tarık, et al.
Publicado: (2022)

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2023)

Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2005)

Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae
por: Zha, Lei, et al.
Publicado: (2022)

1230. Evaluation of the Interplay Between β-lactamases and Porin Production on β-Lactam MICs in Klebsiella pneumoniae
por: Whitney, Alyssa K, et al.
Publicado: (2021)

AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India
por: Gupta, Varsha, et al.
Publicado: (2012)

Management of clinical infections of Escherichia coli by new β-lactam/β-lactamase inhibitor combinations
por: Kadry, Ashraf Ahmed, et al.
Publicado: (2022)

BADAN-conjugated β-lactamases as biosensors for β-lactam antibiotic detection
por: Au, Ho-Wah, et al.
Publicado: (2020)

Cryptic β-Lactamase Evolution Is Driven by Low β-Lactam Concentrations
por: Fröhlich, Christopher, et al.
Publicado: (2021)

Genomic Characterization of KPC-31 and OXA-181 Klebsiella pneumoniae Resistant to New Generation of β-Lactam/β-Lactamase Inhibitor Combinations
por: Muresu, Narcisa, et al.
Publicado: (2022)

Fluoroquinolones versus β-Lactam/β-Lactamase Inhibitors in Outpatients with Chronic Obstructive Pulmonary Disease and Pneumonia: A Nationwide Population-Based Study
por: Lin, Kuan-Yin, et al.
Publicado: (2015)

Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms
por: Martin, Juan F., et al.
Publicado: (2022)

In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates
por: Li, Fu, et al.
Publicado: (2018)

Antibiofilm Activity of β-Lactam/β-Lactamase Inhibitor Combination against Multidrug-Resistant Salmonella Typhimurium
por: Laure, Nana Nguefang, et al.
Publicado: (2022)

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex
por: Economou Lundeberg, Elin, et al.
Publicado: (2023)

Time-resolved β-lactam cleavage by L1 metallo-β-lactamase
por: Wilamowski, M., et al.
Publicado: (2022)

Synthesis and biological evaluation of novel β-lactam-metallo β-lactamase inhibitors
por: Shungube, Mbongeni, et al.
Publicado: (2023)

166. Activity of a Novel β-lactamase Inhibitor QPX7728 Combined With β-lactams Against st258 klebsiella Pneumoniae and st131 escherchia Coli Isolates Producing β-lactamases
por: Castanheira, Mariana, et al.
Publicado: (2020)

Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
por: Tan, Che-Kim, et al.
Publicado: (2019)

Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials
por: Lu, Li-Chin, et al.
Publicado: (2020)

Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial Pseudomonas aeruginosa
por: Muddassir, Maria, et al.
Publicado: (2021)

β-lactam resistance associated with β-lactamase production and porin alteration in clinical isolates of E. coli and K. pneumoniae
por: Khalifa, Sara M., et al.
Publicado: (2021)

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Yang, Tsung-Ying, et al.
Publicado: (2020)

Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae
por: Luo, Hong, et al.
Publicado: (2021)

The Importance of Porins and β-Lactamase in Outer Membrane Vesicles on the Hydrolysis of β-Lactam Antibiotics
por: Kim, Si Won, et al.
Publicado: (2020)

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
por: Palwe, Snehal, et al.
Publicado: (2021)

Extended Versus Intermittent Meropenem Infusion in the Treatment of Nosocomial Pneumonia: A Retrospective Single-Center Study
por: Hyun, Dong-gon, et al.
Publicado: (2023)

Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
por: Harris, Patrick N A, et al.
Publicado: (2015)

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers
por: Mallalieu, Navita L., et al.
Publicado: (2020)

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa
por: Haines, Robbie R., et al.
Publicado: (2022)

Chemiluminescence Detection of Hydrogen Sulfide Release by β-Lactamase-Catalyzed β-Lactam Biodegradation: Unprecedented Pathway for Monitoring β-Lactam Antibiotic Bacterial Resistance
por: Gholap, Sachin Popat, et al.
Publicado: (2021)

Structural Variabilities in β-Lactamase (blaA) of Different Biovars of Yersinia enterocolitica: Implications for β-Lactam Antibiotic and β-Lactamase Inhibitor Susceptibilities
por: Singhal, Neelja, et al.
Publicado: (2015)

Editorial for the Special Issue: “Targeting β-Lactamases to Fight Bacterial Resistance to β-Lactam Antibiotics”
por: Pozzi, Cecilia
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r8gh20cse56in7qfp0a8166tsf